184 related articles for article (PubMed ID: 10865931)
1. Choosing drug therapy for patients with hyperlipidemia.
Safeer RS; Lacivita CL
Am Fam Physician; 2000 Jun; 61(11):3371-82. PubMed ID: 10865931
[TBL] [Abstract][Full Text] [Related]
2. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
3. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
4. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
Jones PH
Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
6. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
9. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Balbisi EA
Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
[TBL] [Abstract][Full Text] [Related]
10. LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Phillips W; Schaefer S
Prev Cardiol; 2010; 13(2):69-71. PubMed ID: 20377808
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Koren MJ; Hunninghake DB;
J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
[TBL] [Abstract][Full Text] [Related]
12. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
Backes JM; Gibson CA
Ann Pharmacother; 2005 Mar; 39(3):523-6. PubMed ID: 15671087
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
14. Niacin-based therapy for dyslipidemia: past evidence and future advances.
Ito MK
Am J Manag Care; 2002 Sep; 8(12 Suppl):S315-22. PubMed ID: 12240703
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
16. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Duvall WL; Blazing MA; Saxena S; Guyton JR
J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
[TBL] [Abstract][Full Text] [Related]
17. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
Stone NJ; Bilek S; Rosenbaum S
Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
19. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
[TBL] [Abstract][Full Text] [Related]
20. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]